Autopsy report · NCT05013437

Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

“The original principal Investigator left the institution.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Early Phase 1

Sponsor

Koen van Besien

Sponsor type

University, hospital or other

Conditions

Multiple Myeloma

Interventions

Evomela; Next Generation Sequencing; Prochlorperazine; Acetaminophen; Diphenhydramine

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
  “Original Principal Investigator left the institution.” (99% match in meaning)
• Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
  “Principal investigator left the institution.” (97% match in meaning)
• Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders
  “the Principal Investigator left the institution” (97% match in meaning)
• Identification and Characterization of Molecular Markers in Musculoskeletal Tumors
  “Principal Investigator has left the Institution” (91% match in meaning)
• Effect of Virtual Reality Training by Novices on Laparoscopic Cholecystectomy in a Porcine Model
  “Principal investigator left institution.” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.